Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | AGER | Q15109 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11432868 | 0.84 | CCR5 (0.50) | ADAMTS4APOBEC3GHSD11B1CCR5KMT2A | |
| SCHEMBL2917368 | 0.82 | ADAMTS4 (0.46) | ADAMTS4APOBEC3GHSD11B1CCR5KMT2A | |
| SCHEMBL25525118 | 0.82 | CCR5 (0.53) | ADAMTS4APOBEC3GHSD11B1CCR5KMT2A | |
| SCHEMBL2917372 | 0.82 | ADAMTS4 (0.46) | ADAMTS4APOBEC3GHSD11B1CCR5KMT2A | |
| SCHEMBL14798295 | 0.82 | ADAMTS4 (0.58) | ADAMTS4APOBEC3GHSD11B1KMT2AALDH1A1 | |
| SCHEMBL2917367 | 0.82 | ADAMTS4 (0.46) | ADAMTS4APOBEC3GHSD11B1CCR5KMT2A | |
| SCHEMBL12907960 | 0.82 | ADAMTS4 (0.58) | ADAMTS4APOBEC3GHSD11B1KMT2AALDH1A1 | |
| SCHEMBL12180441 | 0.80 | AGER (0.71) | ALDH1A1AGERCA12CA9LMNA | |
| SCHEMBL25520498 | 0.79 | SMN1; SMN2 (0.50) | ADAMTS4APOBEC3GHSD11B1CCR5KMT2A | |
| SCHEMBL4613713 | 0.79 | APOBEC3G (0.54) | APOBEC3GHSD11B1CCR5KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746149-A | 1,2, 4-oxadiazole derivatives as liver X receptor agonists | 诺华股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-105121444-B | Cyano ethyl Pyrazolopyridine ketone as the other than ring type of JANUS kinase inhibitors | 默沙东公司 | 2018-02-16 | — | — | CN | claimed |
| EP-2976341-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | claimed |
| WO-2014146493-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-25 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4065228-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | Novartis AG (CH) | 2022-10-05 | — | — | EP | disclosed |
| CN-114746149-A | 1,2, 4-oxadiazole derivatives as liver X receptor agonists | 诺华股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022140390-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | ADAMTS4 2573/4885APOBEC3G 3878/4885HSD11B1 1906/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ADAMTS4 1820/4885APOBEC3G 3966/4885HSD11B1 1837/4885 |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | HDAC6, PSMG3, PSMB2 | ADAMTS4 2009/4885APOBEC3G 3288/4885HSD11B1 2725/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ADAMTS4 1820/4885APOBEC3G 3966/4885HSD11B1 1837/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | ADAMTS4 2573/4885APOBEC3G 3878/4885HSD11B1 1906/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ADAMTS4 2573/4885APOBEC3G 3878/4885HSD11B1 1906/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ADAMTS4 2916/4885APOBEC3G 3528/4885HSD11B1 1495/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | ADAMTS4 1221/4885APOBEC3G 4862/4885HSD11B1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.